The Added Value of Longitudinal Imaging for Preclinical In vivo Efficacy Testing of Therapeutic Compounds against Cerebral Cryptococcosis - Archive ouverte HAL Access content directly
Journal Articles Antimicrobial Agents and Chemotherapy Year : 2020

The Added Value of Longitudinal Imaging for Preclinical In vivo Efficacy Testing of Therapeutic Compounds against Cerebral Cryptococcosis

(1, 2) , (1, 2) , (1, 2) , (3) , (4) , (5, 6) , (2, 1) , (2, 1)
1
2
3
4
5
6

Abstract

Brain infections with Cryptococcus neoformans are associated with significant morbidity and mortality. Cryptococcosis typically presents as meningoencephalitis or fungal mass lesions called cryptococcomas. Despite frequent in vitro discoveries of promising novel antifungals, the clinical need for drugs that can more efficiently treat these brain infections remains. A crucial step in drug development is the evaluation of in vivo drug efficacy in animal models. This mainly relies on survival studies or post-mortem analyses in large groups of animals, but these techniques only provide information on specific organs of interest at predefined time points. In this proof-of-concept study, we validated the use of non-invasive preclinical imaging to obtain longitudinal information on the therapeutic efficacy of amphotericin B or fluconazole monotherapy in meningoencephalitis and cryptococcoma mouse models. Bioluminescence imaging (BLI) enabled the rapid in vitro and in vivo evaluation of drug efficacy while complementary high-resolution anatomical information obtained by magnetic resonance imaging (MRI) of the brain allowed a precise assessment of the extent of infection and lesion growth rates. We demonstrated a good correlation between both imaging readouts and the fungal burden in various organs. Moreover, we identified potential pitfalls associated with the interpretation of therapeutic efficacy based solely on post-mortem studies, demonstrating the added value of this non-invasive dual imaging approach compared to standard mortality curves or fungal load endpoints. This novel preclinical imaging platform provides insights in the dynamic aspects of the therapeutic response and facilitates a more efficient and accurate translation of promising antifungal compounds from bench to bedside.
Fichier principal
Vignette du fichier
Vanherp et al AAC 2020.pdf (2.11 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

pasteur-02652024 , version 1 (29-05-2020)

Identifiers

Cite

Liesbeth Vanherp, Jennifer Poelmans, Amy Hillen, Guilhem Janbon, Matthias Brock, et al.. The Added Value of Longitudinal Imaging for Preclinical In vivo Efficacy Testing of Therapeutic Compounds against Cerebral Cryptococcosis. Antimicrobial Agents and Chemotherapy, 2020, 64 (7), pp.e00070-20. ⟨10.1128/AAC.00070-20⟩. ⟨pasteur-02652024⟩

Collections

PASTEUR
36 View
30 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More